Aosaikang declared 3.1 antifungal carbaryl acetate API
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the CFDA website on March 27, the API of kapofungin acetate, a class 3.1 new drug, which was applied for production by arcmecon, was accepted At present, only the original drug kapofungin acetate for injection is on sale in China, and there is no domestic enterprise producing kapofungin acetate and related preparations Kapofungin acetate for injection is used for the treatment of invasive aspergillosis and invasive candidiasis The original research drug is "cosis" developed by mosadon, which entered the Chinese market in 2009 According to CFDA data, at present, there are no domestic enterprises that have the production approval documents for carbaryl acetate API There are 4 enterprises applying for carbaryl acetate API and 3 enterprises applying for carbaryl acetate for injection.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
